Avivagen Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VIV.V research report →
Companywww.avivagen.com
Avivagen Inc. , a life sciences company, focuses on developing and commercializing products for livestock feeds that support immune function and help animals to achieve their growth and productivity. The company offers OxC-beta Livestock, a premix for inclusion in livestock feeds; Vivamune health chews for dogs; Dr.
- CEO
- G. F. Kym Anthony
- IPO
- 2007
- Employees
- 13
- HQ
- Ottawa, ON, CA
Price Chart
Valuation
- Market Cap
- $776.95K
- P/E
- -0.11
- P/S
- 0.83
- P/B
- -0.11
- EV/EBITDA
- -2.69
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 42.62%
- Op Margin
- -99.40%
- Net Margin
- -645.91%
- ROE
- 122.10%
- ROIC
- -916.23%
Growth & Income
- Revenue
- $939.17K · -27.53%
- Net Income
- $-6,066,206 · 5.13%
- EPS
- $-0.09 · 23.42%
- Op Income
- $-933,530
- FCF YoY
- 32.36%
Performance & Tape
- 52W High
- $0.10
- 52W Low
- $0.01
- 50D MA
- $0.01
- 200D MA
- $0.01
- Beta
- 1.00
- Avg Volume
- 74.81K
Get TickerSpark's AI analysis on VIV.V
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our VIV.V Coverage
We haven't published any research on VIV.V yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate VIV.V Report →